Earnings Feed
Start Free
Alamar Biosciences, Inc.·4

Apr 20, 8:37 PM ET

Witney Frank 4

4 · Alamar Biosciences, Inc. · Filed Apr 20, 2026

Research Summary

AI-generated summary of this filing

Updated

Alamar Biosciences (ALMR) Director Witney Frank Reclassifies 206,781 Shares

What Happened
Witney Frank, a director of Alamar Biosciences, reported a series of "other" derivative transactions on 2026-04-20 that show matched dispositions and acquisitions totaling 206,781 shares (49,627; 33,085; 124,069). All transactions are reported at $0.00 and are coded as derivative "other acquisition or disposition (J)," indicating reclassification/conversion activity rather than open-market buys or sales. No cash changed hands in these entries.

Key Details

  • Transaction date: 2026-04-20; all reported at $0.00 (derivative transactions, code J).
  • Individual entries: disposed and reacquired 49,627; 33,085; and 124,069 shares (pairs of equal disposed/acquired amounts).
  • Total affected shares: 206,781.
  • Shares owned after transaction: not disclosed in the supplied filing details.
  • Footnotes: F1 notes Class B Common was reclassified into Common immediately prior to the issuer's IPO; F2 indicates some shares are fully vested; F3 and F4 describe option vesting schedules (monthly over 48 months and a 25% cliff then monthly vesting, respectively).
  • Filing timeliness: reported on the same date (2026-04-20) — appears timely.

Context
These entries look administrative (conversion/reclassification of derivative interests—e.g., Class B to Common stock around an IPO) rather than purchases or sales that signal a trading view. For retail investors, note this is not an open-market purchase or cash sale; some related holdings are subject to vesting schedules per the footnotes, while others are fully vested.

Insider Transaction Report

Form 4
Period: 2026-04-20
Alamar Biosciences, Inc.ALMR
Witney Frank
Director
Transactions
  • Other

    Stock Option (Right to Buy)

    [F1][F2]
    2026-04-20−49,627→ 0 total
    Exercise: $0.59Exp: 2031-04-20→ Class B Common Stock (49,627 underlying)
  • Other

    Stock Option (Right to Buy)

    [F1][F2]
    2026-04-20+49,627→ 49,627 total
    Exercise: $0.59Exp: 2031-04-20→ Common Stock (49,627 underlying)
  • Other

    Stock Option (Right to Buy)

    [F1][F3]
    2026-04-20−33,085→ 0 total
    Exercise: $3.10Exp: 2035-04-15→ Class B Common Stock (33,085 underlying)
  • Other

    Stock Option (Right to Buy)

    [F1][F3]
    2026-04-20+33,085→ 33,085 total
    Exercise: $3.10Exp: 2035-04-15→ Common Stock (33,085 underlying)
  • Other

    Stock Option (Right to Buy)

    [F1][F4]
    2026-04-20−124,069→ 0 total
    Exercise: $7.60Exp: 2036-01-14→ Class B Common Stock (124,069 underlying)
  • Other

    Stock Option (Right to Buy)

    [F1][F4]
    2026-04-20+124,069→ 124,069 total
    Exercise: $7.60Exp: 2036-01-14→ Common Stock (124,069 underlying)
Footnotes (4)
  • [F1]Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock.
  • [F2]Fully vested.
  • [F3]The shares subject to the option vest in equal monthly installments over 48 months measured from January 1, 2025, subject to the reporting person's continuous service as of each such vesting date.
  • [F4]Twenty-five percent of the shares subject to the option vest on January 15, 2027, and 1/48th of the shares vest monthly thereafter, subject to the reporting person's continuous service through each such vesting date.
Signature
/s/ Timothy White, Attorney-in-Fact|2026-04-20

Documents

1 file
  • 4
    form4-04212026_120458.xmlPrimary